OBiO Technology
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $100M
Overview
Chinese biotech developing CRISPR-based gene and cell therapies for oncology and genetic disorders.
OncologyRare Diseases
Technology Platform
CRISPR-based gene editing systems combined with proprietary viral vector engineering, particularly optimized AAV vectors for in vivo delivery and engineered cell therapy platforms.
Opportunities
Leveraging China's large patient population and supportive regulatory environment for advanced therapies, plus growing demand for CDMO services in the gene therapy space.
Risk Factors
Intense competition in gene and cell therapy, technical challenges in delivery and editing efficiency, and regulatory uncertainties in emerging therapy categories.
Competitive Landscape
Competes with Chinese gene therapy companies like JW Therapeutics and EdiGene; differentiates through integrated CDMO capabilities and focus on optimized delivery systems.